drug evaluation, preclinical

MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
Iñaki Eguren-Santamaria, Eva Fernández de Piérola, Gracián Camps, Paula Martín-Muñoz, María Campos, Doina Cuculescu, Inmaculada Aguilera-Buenosvinos, Inmaculada Rodríguez López, Rafael Salido-Vallejo, Raluca Alexandru, Carlos E De Andrea, Laura Álvarez-Gigli, Pedro Berraondo, Ignacio Melero, Miguel F Sanmamed

Journal for ImmunoTherapy of Cancer Sep 2024, 12 (9) e008516; DOI: 10.1136/jitc-2023-008516
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade
Jason K Cullen, Pei-Yi Yap, Blake Ferguson, Zara C Bruce, Motoko Koyama, Herlina Handoko, Kevin Hendrawan, Jacinta L Simmons, Kelly M Brooks, Jenny Johns, Emily S Wilson, Marjorie M A de Souza, Natasa Broit, Praphaporn Stewart, Daniel Shelley, Tracey McMahon, Steven M Ogbourne, Tam Hong Nguyen, Yi Chieh Lim, Alberto Pagani, Giovanni Appendino, Victoria A Gordon, Paul W Reddell, Glen M Boyle, Peter G Parsons

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e006602; DOI: 10.1136/jitc-2022-006602
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
Celia Gomar, Claudia Augusta Di Trani, Angela Bella, Leire Arrizabalaga, Jose Gonzalez-Gomariz, Myriam Fernandez-Sendin, Maite Alvarez, Joan Salvador Russo-Cabrera, Nuria Ardaiz, Fernando Aranda, Timo Schippers, Marisol Quintero, Ignacio Melero, Klaus K Orlinger, Henning Lauterbach, Pedro Berraondo

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008287; DOI: 10.1136/jitc-2023-008287
Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway
Mari Tone, Kota Iwahori, Michinari Hirata, Azumi Ueyama, Akiyoshi Tani, Jun-Ichi Haruta, Yoshito Takeda, Yasushi Shintani, Atsushi Kumanogoh, Hisashi Wada

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008334; DOI: 10.1136/jitc-2023-008334
Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells
Sarah Ducellier, Mélanie Demeules, Boris Letribot, Massimiliano Gaetani, Chloé Michaudel, Harry Sokol, Abdallah Hamze, Mouad Alami, Mégane Nascimento, Sébastien Apcher

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e007588; DOI: 10.1136/jitc-2023-007588
Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment
Rita Turpin, Ruixian Liu, Pauliina M Munne, Aino Peura, Jenna H Rannikko, Gino Philips, Bram Boeckx, Natasha Salmelin, Elina Hurskainen, Ilida Suleymanova, July Aung, Elisa M Vuorinen, Laura Lehtinen, Minna Mutka, Panu E Kovanen, Laura Niinikoski, Tuomo J Meretoja, Johanna Mattson, Satu Mustjoki, Päivi Saavalainen, Andrei Goga, Diether Lambrechts, Jeroen Pouwels, Maija Hollmén, Juha Klefström

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e008053; DOI: 10.1136/jitc-2023-008053
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer
Antons Martincuks, Chunyan Zhang, Theresa Austria, Yi-Jia Li, Rui Huang, Nicole Lugo Santiago, Adrian Kohut, Qianqian Zhao, Rosemarie Martinez Borrero, Binghui Shen, Mihaela Cristea, Edward W Wang, Mihae Song, Lorna Rodriguez-Rodriguez, Hua Yu

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e007716; DOI: 10.1136/jitc-2023-007716
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy
Christina Kober, Julian Roewe, Norbert Schmees, Lars Roese, Ulrike Roehn, Benjamin Bader, Detlef Stoeckigt, Florian Prinz, Mátyás Gorjánácz, Helge Gottfried Roider, Catherine Olesch, Gabriele Leder, Horst Irlbacher, Ralf Lesche, Julien Lefranc, Mine Oezcan-Wahlbrink, Ankita Sati Batra, Nirmeen Elmadany, Rafael Carretero, Katharina Sahm, Iris Oezen, Frederik Cichon, Daniel Baumann, Ahmed Sadik, Christiane A Opitz, Hilmar Weinmann, Ingo V Hartung, Bertolt Kreft, Rienk Offringa, Michael Platten, Ilona Gutcher

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007495; DOI: 10.1136/jitc-2023-007495
BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1
Young-Seung Kim, Seung-Hoon Lee, Andrew H Park, Chunai Wu, Bong-Ki Hong, Hyunjin Jung, Steven H Lin, Stephen S Yoo

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008303; DOI: 10.1136/jitc-2023-008303
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells
Ian-Ian Ng, Jiaqi Zhang, Tingzhong Tian, Qi Peng, Zheng Huang, Kaimin Xiao, Xiyue Yao, Lui Ng, Jianyang Zeng, Haidong Tang

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008254; DOI: 10.1136/jitc-2023-008254

Main menu

drug evaluation, preclinical

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

drug evaluation, preclinical

Pages